Straits Times Index
3,314.05 +0.57 (+0.02%) S&P 500
5,308.13 +4.86 (+0.09%) Dow
39,806.77 -196.82 (-0.49%) Nasdaq
16,794.88 +108.91 (+0.65%) Bitcoin USD
69,719.04 +3,339.39 (+5.03%) CMC Crypto 200
1,488.17 +133.75 (+9.89%)
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
| Previous close | 5,850.40 |
| Open | 5,810.95 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5,800.15 - 5,849.15 |
| 52-week range | 4,384.25 - 6,505.90 |
| Volume | |
| Avg. volume | 377,440 |
| Market cap | 967.528B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 17.36 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 40.00 (0.69%) |
| Ex-dividend date | 15 Jul 2024 |
| 1y target est | N/A |
- Business Wire
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
HYDERABAD, India, May 07, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
